Sipahi, Oguz ResatMermer, SinanDemirdal, TunaUlu, Ashhan CandevirFillatre, PierreOzcem, Selin BardakKaya, SafakSener, AlperBulut, CemalTekin, RecepKahraman, HasipOzgiray, ErkinYurtseven, TaskinSipahi, HilalArda, BilginPullukcu, HusnuTasbakan, MeltemYamazhan, TansuAydemir, SohretUlusoy, Sercan2019-10-272019-10-2720180303-84671872-6968https://doi.org/10.1016/j.clineuro.2018.06.008https://hdl.handle.net/11454/30001Objectives: In this study we retrospectively reviewed A. baumannii meningitis cases treated with tigecycline including regimens and evaluated the efficacy of tigecycline in the therapy. Patients and Methods: Study was performed in seven tertiary-care educational hospitals from five cities of Turkey and one center from France. We extracted data and outcomes of all adult (aged > 18) patients with culture proven A. baumannii meningitis treated with tigecycline including antibiotic therapy until April 2016. Results: A total of 23 patients (15 male and eight female) fulfilled our inclusion criteria. All Acinetobacter strains were carbapenem-resistant and susceptible to tigecycline. Six cases received tigecycline monotherapy while 17 received tigecycline including combination therapy (10 with colistin, 4 with netilmicin, 3 with amikacin, 4 with meropenem). Seven of 23 cases (30%) died during the tigecycline including therapy (1 in monotherapy, 4 in colistin, 2 in netilmicin, 1 amikacin, one case received tigecycline + netilmicin followed by tigecycline + colistin). Hence, overall end of treatment (EOT) success was 70%. However, since further 27% died due to additional nosocomial infections, overall clinical success (relieved symptoms at the EOT and one-month post therapy survival without any relapse or reinfection) decreased to 43%. Conclusion: We conclude that tigecycline may be an alternative in the salvage treatment of nosocomial multi drug-resistant Acinetobacter spp. meningitis. Acinetobacter spp. Meningitis.en10.1016/j.clineuro.2018.06.008info:eu-repo/semantics/closedAccessAcinetobacter baumanniiMeningitisGlycylcyclineMultidrug resistant bacteriaCarbapenem-resistantArticle1723138WOS:00044298000000629960893Q2Q3